In vivo study of the metabotropic glutamate receptor type 5 (mGluR5) in relation to adenosine signalling and neuroinflammation in experimental Parkinson' disease. KU Leuven
With an ageing population, the search continues for curative or at least improved symptomatic treatment of neurodegenerative disorders such as Parkinson’s disease (PD). Current treatments are primarily aimed at restoring basal ganglia signaling through targeting of the striatal dopaminergic synapse, most often with the dopamine precursor levodopa. However, these interventions do not slow down the disease or prevent the occurrence of ...